Medicines Co. Stock Halted Ahead Of FDA Review Of Heart Drug

The Medicines Co. said Wednesday the Nasdaq has halted trading of its stock ahead of a review of its cangrelor drug by the the U.S. Food and Drug Administration. The drug is a treatment aimed at reducing thrombotic cardiovascular events in patients with coronary artery disease. An FDA committee will review the company's new drug application for the treatment at a meeting scheduled for 8.00 a.m. ET. Shares have gained 4.7% in the year so far, while the S&P 500 has gained 1.8%.